Payment overview · 2025
General Payments
$1,112.51
58 reported records · 18 companies
Healthcare provider profile · identity verified
Brianne Bagwell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SALEM, OH · NPI 1730435975
Verified facts
What the public records show
CMS Open Payments records show Brianne Bagwell, M.D. received $1,112.51 in general payments during 2025 across 58 reported records.
PFIZER INC. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.64 | 16.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.02 | 13.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.39 | 13.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.34 | 8.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.02 | 8.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.16 | 7.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.74 | 4.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.37 | 4.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.84 | 4.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.14 | 3.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.36 | 3.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.98 | 3.4% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $23.13 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.36 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 1.7% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.93 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.42 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,112.51 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.95 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $150.03 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.56 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.27 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.34 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.16 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.36 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.03 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.75 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.62 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.67 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 194 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 33 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 93 |
| Omeprazole | Omeprazole | 372 | 95 |
| Lisinopril | Lisinopril | 257 | 57 |
| Losartan Potassium | Losartan Potassium | 235 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 52 |
| Eliquis | Apixaban | 194 | 33 |
| Famotidine | Famotidine | 167 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 40 |
| Metformin Hcl | Metformin Hcl | 150 | 32 |
| Simvastatin | Simvastatin | 143 | 30 |
| Potassium Chloride | Potassium Chloride | 139 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 29 |
| Furosemide | Furosemide | 120 | 35 |
| Gabapentin | Gabapentin | 111 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 24 |
| Alendronate Sodium | Alendronate Sodium | 103 | 32 |
| Jardiance | Empagliflozin | 98 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 19 |
| Sertraline Hcl | Sertraline Hcl | 96 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 18 |
| Donepezil Hcl | Donepezil Hcl | 67 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 17 |
| Ozempic | Semaglutide | 66 | 11 |
| Bupropion Xl | Bupropion Hcl | 64 | 14 |
| Carvedilol | Carvedilol | 62 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 12 |
| Buspirone Hcl | Buspirone Hcl | 61 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Bumetanide | Bumetanide | 58 | 11 |
| Spironolactone | Spironolactone | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 53 | 19 |
| Montelukast Sodium | Montelukast Sodium | 52 | 12 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 12 |
| Atenolol | Atenolol | 32 | suppressed |
| Jantoven | Warfarin Sodium | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 22 |
| Digoxin | Digoxin | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 23 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Estradiol | Estradiol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,112.51 · 58 records | PFIZER INC. | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, ISTURISA, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error